medRxiv
October 5, 2026
Praachi Tiwari, Sandeep M. Nayak, Nathan D. Sepeda et al.
preprint
Importance: Obsessive-Compulsive Disorder (OCD) has a 2% global prevalence, but only about 50% of patients respond to conventional treatment, underscoring the need for additional effective interventions. Objective: To assess the feasibility, safety, and preliminary evidence for efficacy of repeated psilocybin administration in OCD patients who had previously attempted psychotherapy or...
Journal of Psychiatric Research
October 1, 2026
Erica Kaczmarek, Sabrina Wong, Noah Chisamore et al.
Background Anhedonia is a debilitating core feature of mood disorders, and is associated with significant functional impairment and poor quality of life. Psilocybin has recently emerged as a novel antidepressant treatment in MDD, however, its effects on anhedonia specifically have yet to be systematically reviewed. This review evaluates available clinical and pre-clinical research, exploring...
Psychedelics
October 1, 2026
Christina Chwyl, Kim Hoffman, Jason B. Luoma et al.
Background Real-world psilocybin use outpaces evidence-based guidance and accessible professional support; understanding psilocybin safety strategy and resource utilization is important for informing education and dissemination initiatives. Methods This qualitative study explored the perspectives of Oregon residents ( N = 31) who plan to/have used psilocybin, employing thematic analysis of...
JAMA Network Open
October 1, 2026
Kim Madden, Breanne Flood, Imad Kashir et al.
Psilocybin has received increased attention as a potential therapeutic intervention, but it is unclear whether news media reporting reflects the strengths and limitations of the clinical trial evidence. To describe the annual counts of published clinical trials of therapeutic psilocybin and contemporaneous media articles and compare tone, efficacy, and safety messaging. This systematic review...
Brain and Behavior
October 2026
Ruiqi Rachel Luo, David J. Berlowitz, Alexander Bryson et al.
Psilocybin is a naturally occurring classic psychedelic associated with widespread changes in brain function and promising therapeutic outcomes in several neuropsychiatric disorders. Complementing these findings, qualitative studies following psilocybin administration have revealed diverse and highly individual effects across multiple domains of subjective experience. However, little is known...
Psychedelics
October 1, 2026
Lorenzo Miller, Cordelia Kuiper Rauch, Keren Chen et al.
Background Psilocybin-assisted therapy has shown robust antidepressant effects among individuals with major depressive disorder (MDD); however, mechanisms of the treatment remain unclear. Depression has been associated with diminished feelings of connectedness to oneself, others, and the world, and psilocybin is thought to facilitate connectedness. This analysis of an open-label trial of...
Journal of Affective Disorders Reports
October 1, 2026
Kevin Byrne, Madeleine Odette, Eric L Garland et al.
ABSTRACT Background Healthcare workers experienced amplified depression and burnout during COVID-19. Both Mindfulness Based Stress Reduction (MBSR) and psilocybin have been shown to reduce depressive symptoms in this population, however the psychological mechanisms by which adding psilocybin to mindfulness training improves depression and trait mindfulness remain incompletely characterized....
Drug Science Policy and Law
October 1, 2026
Gabriel Bélanger, Sue-Ling Chang, Marianne Masse-Grenier et al.
Psilocybin remains prohibited in most jurisdictions, but Switzerland, Canada, and Australia have established tightly regulated clinical access pathways. In this developing landscape, prescribers are pivotal to safe access and must navigate conflicting guidance, uncertainty, and legal risk. Clarifying how current regulations define prescribers’ roles is therefore important for understanding how...
Psychedelics
October 1, 2026
Diego Borbón
In April 2025, New Mexico enacted the Medical Psilocybin Act, establishing the first legislated statewide medical psilocybin program and becoming the third state to authorize supervised psilocybin use. The Act directs the New Mexico Department of Health to build a regulated system where licensed clinicians provide psilocybin to qualified patients in approved settings for treatment-resistant...
Psychology Archives
September 30, 2026
Hüseyin Beyköylü, Merijn Mestdagh, Fred Hasselman et al.
Derived results from an observational study of fourteen adults attending legal psilocybin truffle retreats in the Netherlands. Includes the per-participant time series of the collective variable, dynamic complexity and detected levels; the per-participant summary table; item diagnostics and collective variable validation; the timing of destabilization; two sensitivity analyses; the full...